JPRN-UMIN000005577已完成未知
An Open-Label Trial of Vesicare(Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) - Effect of Vesicare on IBS-D
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Uncontrolled heart disease or arrhythmias. History of major gastrointestinal surgery. Urinary retention. Narrow angle glaucoma. myasthenia gravis. Severe constipation.
研究者
相似试验
已完成
不适用
PK_AL_PREGNANCY_KENYAMalariaPACTR201211000451437Kenya Medical Research Institute75
进行中（未招募）
1 期
Clinical study in patients with bladder cancerTreatment of patients with recurrent non-muscle invasive bladder cancerMedDRA version: 19.0 Level: PT Classification code 10005005 Term: Bladder cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005330-58-NLSAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung)39
进行中（未招募）
1 期
Clinical Trial to investigate the bioavailability, safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizuresrefractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 yearsMedDRA version: 20.0Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852EUCTR2012-001091-11-HRBIAL - Portela & Ca, S.A.24
进行中（未招募）
1 期
Clinical Trial to investigate the bioavailability, safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizuresrefractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 yearsMedDRA version: 21.1Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852EUCTR2012-001091-11-CZBIAL - Portela & Ca, S.A.24
进行中（未招募）
1 期
Clinical Trial to investigate the safety and tolerability ofEslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures for one yearrefractory epilepsy with partial-onset seizures in children aged from 1month to < 2 yearsMedDRA version: 20.0Level: LLTClassification code 10065336Term: Partial epilepsySystem Organ Class: 100000004852EUCTR2016-001072-29-ITBIAL - Portela & Ca, S.A.24